The application of immunotherapy [e.g., checkpoint inhibitors against cytotoxic T lymphocyte antigen 4 (CTLA-4) and/or programmed death 1 (PD-1)], molecular targeted anti-tumor therapy [B-Raf proto-oncogene (BRAF), mitogen-activated protein kinase (MEK)], and neoadjuvant therapy has greatly improved the survival prognosis of CM patients(1, 5–7). The gene discussed is BRAF; the disease is cutaneous mastocytosis.